Aerie Pharmaceuticals — Technical Presentation (September 2021)
29 slides from Aerie Pharmaceuticals's technical presentation, Sep 15, 2021
Slide 1: Phase 2b Study of AR-15512 for Dry Eye Disease (COMET-1)
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease Study AR-15512-CS201 (COMET-1) September 2021 Exhibit 99.2
Slide 2: Important Information
Important Information Any discussion of the potential use or expected success of our product candidates is subject to our regulatory approval. The information in this presentation is current only as of its date and may have changed prior to it being read or may change in the future. We undertake no
Slide 3: Dry Eye
Dry Eye 1Stonecipher et al. Therapeutics and Clinical Risk Management 2013 Over 30 million individuals in the US alone suffer from dry eye, yet less than 10% are treated. Prevalence of dry eye continues to rise as a result of an aging population, and more frequent use of contact lenses, computers, s
Slide 4: Executive Summary
Executive Summary In this Phase 2b clinical study, two concentrations (0.0014% and 0.003%) of AR-15512 dosed twice daily were evaluated for safety and efficacy vs. vehicle in subjects with dry eye. Statistically significant efficacy was demonstrated across multiple pre-specified symptom and sign end
Slide 5: TRPM8 receptors and AR-15512 mechanism
TRPM8 (transient receptor potential melastatin) receptors are cold-sensitive thermoreceptors that play key role in tear film homeostasis.1-2 Located on eyelid and cornea. TRPM8 channels detect drops in corneal temperature associated with tear evaporation on ocular surface. AR-15512 is a potent and h
Slide 6: Study Design
Study Design Objective: To evaluate the safety, tolerability, and efficacy of 2 doses (0.0014%, 0.003%) topical ophthalmic AR-15512 compared to vehicle administered twice daily in subjects with dry eye disease (DED). Design: Double-masked, vehicle-controlled multicenter randomized study with environ
Slide 7: Key Inclusion Criteria
Key Inclusion Criteria Male or female, 30 years of age or older at the Screening visit. Have a history of dry eye disease within the previous 6 months. Have used, and/or desired to use artificial tears for dry eye disease (DED) within 2 months prior to the Screening visit. Symptoms of DED based Ocul
Slide 8: Key Exclusion Criteria
Key Exclusion Criteria History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or subject safety. History of ocular surgery within 1 year prior to the Screenin
Slide 9: Subject Disposition
Subject Disposition 0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Number of Subjects Randomized 121 122 126 Subjects Completed Study, no. (%) 114 (94.2) 115 (94.3) 116 (92.1) Subjects Discontinued, no. (%) Adverse Event Withdrawal of Consent Non-Compliant Lost to Follow-up Investigator
Slide 10: Baseline Demographics
Baseline Demographics 0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Age (years) 39 (32.2%) 30 (24.6%) 34 (27.0%) Mean (SD) 65.5 (10.89) 62.6 (13.01) 63.1 (11.90) Range 31 – 85 30 - 87 30 - 90 Gender Female, no (%) 82 (67.8%) 92 (75.4%) 92 (73.0%) Race, no (%) White/Caucasian 97 (80.2%)
Slide 11: Symptoms: Statistically Significant Improvements for 0.003% AR-15512
Symptoms: Statistically Significant Improvements in Endpoints for 0.003% AR-15512 SYMPTOM TIMING Potential FDA endpoint Ocular Discomfort Score (ODS-VAS) Change from Baseline – Ocular Discomfort VAS Day 84 (p=0.028) Yes Mean Ocular Discomfort VAS Day 84 (p=0.039) Yes SANDE Change from Baseline SANDE
Slide 12: Symptoms: Ocular Discomfort (ODS-VAS)
Symptoms: Ocular Discomfort (ODS-VAS) p = 0.23 * p = 0.028 (Primary Endpoint) For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 13: Symptoms: SANDE
Symptoms: SANDE * p = 0.0015 * p = 0.0005 * p = 0.0254 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 14: Symptoms: Eye Dryness (EDS-VAS)
Symptoms: Eye Dryness (EDS-VAS) * p = 0.03 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 15: Symptoms: Ocular Pain (VAS)
Symptoms: Ocular Pain (VAS) p = 0.079 For Investor Use Data on file AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 16: Signs: Statistically Significant Improvements for 0.003% AR-15512
Signs: Statistically Significant Improvements in Endpoints for 0.003% AR-15512 SIGN TIMING Potential FDA endpoint Schirmer Score (Unanesthetized) * Change from Baseline – Schirmer Day 1 (p<0.0001), Day 14 (p<0.0001) Yes % Responders (>10 mm) Day 1 (p<0.0001), Day 14 (p<0.0001) Yes** Conjunctival Red
Slide 17: Signs: Change from Baseline Anesthetized Schirmer
Signs: Change from Baseline Anesthetized Schirmer p = 0.494 (Primary Endpoint) For Investor Use Data on file AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 18: Signs: Change from Baseline Unanesthetized Schirmer
Signs: Change from Baseline Unanesthetized Schirmer * p < 0.0001 * p < 0.0001 * p < 0.0001 * p < 0.0001 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 19: Signs: Unanesthetized Schirmer Responders >10 mm
Signs: Unanesthetized Schirmer Responders >10 mm * p < 0.0001 * p < 0.0001 * p < 0.0001 * p < 0.0001 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 20: Signs: Conjunctival Redness
Signs: Conjunctival Redness * p < 0.022 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 21: Signs: Total Ocular Surface Staining
Signs: Total Ocular Surface Staining * p < 0.012 * p < 0.003 * p < 0.037 For Investor Use Data on file *=p<0.05 AR-15512 is a development stage product candidate and is not approved by any regulatory agency.
Slide 22: Overall Safety
Overall Safety 0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Any Treatment-Emergent AE 57 (47.1%) 63 (51.6) 26 (20.6%) Serious TEAEs 1 (0.8%) 1 (0.8%) 2 (1.6%) Serious TEAEs Related to Study Medication 0 0 0 TEAEs by severity Mild Moderate Severe 50 (41.3%) 5 (4.1%) 2 (1.7%) 59 (48.4%)
Slide 23: Ocular Treatment-Emergent Adverse Events
Ocular Treatment-Emergent Adverse Events 0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Any Ocular Treatment-Emergent AE 51 (42.1%) 59 (48.4%) 13 (10.3%) Ocular TEAE by Severity Mild Moderate Severe 49 (40.5%) 1 (0.8%) 1 (0.8%) 56 (45.9%) 2 (1.6%) 1 (0.8%) 12 (9.5%) 1 (0.8%) 0 Ocular TEA
Slide 24: Ocular Treatment-Emergent Adverse Events by Term
0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Any Ocular Treatment-Emergent AE 51 (42.1%) 59 (48.4%) 13 (10.3%) Eye Disorder 12 (9.9) 6 (4.9) 9 (7.1) Chalazion 0 0 1 (0.8) Conjunctival hemorrhage 0 0 1 (0.8) Conjunctival hyperemia 1 (0.8) 0 0 Conjunctival edema 1 (0.8) 0 0 Corneal epith
Slide 25: Burning or Stinging Upon IP Instillation
Burning or Stinging Upon IP Instillation Overall, 3 subjects discontinued the study early due to instillation site burning (2 in 0.0014% and 1 in 0.003%) and 1 subject discontinued due to instillation site stinging (0.003%) For Investor Use Data on file AR-15512 is a development stage product candid
Slide 26: Non-Ocular Treatment-Emergent Adverse Events
Non-Ocular Treatment-Emergent Adverse Events 0.0014% AR-15512 n=121 0.003% AR-15512 n=122 Vehicle n=126 Any Ocular Treatment-Emergent AE 18 (14.9%) 9 (7.4%) 16 (12.7%) Non-Ocular TEAE by severity Mild Moderate Severe 13 (10.7%) 4 (3.3%) 1 (0.8%) 8 (6.6%) 1 (0.8%) 0 9 (7.1%) 6 (4.8%) 1 (0.8) Non-Ocul
Slide 27: Summary
Summary In this Phase 2b clinical study, 369 dry eye subjects were randomized to one of 3 treatment groups (0.0014% AR-15512, 0.003% AR-15512 or vehicle). Statistically significant efficacy was demonstrated across multiple pre-specified symptom and sign endpoints with 0.003% AR-15512. Symptoms: Ocul
Slide 28: Next Steps
Next Steps: End-of-Phase 2 meeting with FDA in Q1 2022 with Phase 3 initiation in Q2 2022. Plan two 3-month efficacy studies and safety study. Expected NDA submission H1 2024. For Investor Use Data on file AR-15512 is a development stage product candidate and is not approved by any regulatory agency
Slide 29: Background on Presenters
Background on Presenters David Hollander, MD, MBA Chief R&D Officer Cornea-trained ophthalmologist Former leadership roles at Allergan (Global VP and Therapeutic Area Head) and Ora, Inc. (Chief Medical Officer) Michelle Senchyna, PhD Vice President, Clinical Development and Medical Affairs Worked on
Aerie Pharmaceuticals — Technical Presentation (September 2021) on 6ix